Share

June 2015; 2 (3) ArticleOpen Access

Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS

Heather B. Streeter, Rachel Rigden, Keith F. Martin, Neil J. Scolding, David C. Wraith
First published March 12, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000093
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1782

Share

Article Information

vol. 2 no. 3 e93
DOI: 
https://doi.org/10.1212/NXI.0000000000000093
PubMed: 
25798453
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received June 23, 2014
  • Accepted in final form February 10, 2015
  • First Published March 12, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Heather B. Streeter, PhD,
    2. Rachel Rigden, PhD,
    3. Keith F. Martin, PhD,
    4. Neil J. Scolding, PhD, FRCP and
    5. David C. Wraith, PhD
  1. Heather B. Streeter, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Myelin basic protein peptide composition (2) Peptide composition (3)Tolerogenic peptides from myelin basic protein

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Apitove NV, Research Project Leader, 2009-2011

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Apitope NV

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. (1) Apitope NV, 2002-present

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Rachel Rigden, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. During this study I was employed by Apitope Technolgy, as a senior scientist for 2 years.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Apitope Technolgy

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Keith F. Martin, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Apitope Technology (Bristol) Ltd.; Chief Executive Officer

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Apitope International NV

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Neil J. Scolding, PhD, FRCP and
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Practical Neurology; Assistant Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from Genzyme-Sanofi, Merck Serono, Biogen and Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Silverman Foundation have funded research.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. David C. Wraith, PhD
    6. Scientific Advisory Boards:

    1. Apitope Intl NV, Actelion Pharma and Zealand Pharma

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Senior Editor: Immunotherapy: Current http://www.futuremedicine.com/page/journal/imt/editors.jsp

    Patents:

    1. 1. WO2014111841 (A2) ? PEPTIDE: Wraith, D., Streeter, H., Ordonez, L. 2014 2. WO2014111840 (A2) ? PEPTIDE: Wraith, D., Streeter, H. 2014 3. WO2014072958 (A1) ? PEPTIDES: Wraith, D., Streeter, H. 2014 4. WO2013150284 (A1) - TOLERISATION- INDUCING COMPOSITION: Wraith, D., Hill, E. 20135. WO2009071886 (A1) - FVIII PEPTIDES AND THEIR USE IN TOLERISING HAEMOPHILIACS: Wraith, D. 2009 6. WO2009056833 (A2) ? COMPOSITION: Wraith, D., Streeter, H.B. 2009 7. WO2008129296 (A2) ? DISEASE MARKERS: Wraith, D., Streeter, H. 2008 8. WO03064464 (A1) - TOLEROGENIC PEPTIDES FROM MYELIN BASIC PROTEIN: Ponsford, F.M., Mazza, G., Wraith, D.C., Streeter, H.B. 2003 9. WO0216410 (A3) ? PEPTIDE SELECTION METHOD: Wraith, D.C., Anderton, S.M., Mazza, G., Ponsford, M., Streeter, H.B. 2002 10.WO8604242 (A1) - IMPROVEMENTS RELATING TO INFLUENZA VACCINE: Askonas, B.A., Wraith, D.C. 1986

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Has a consultancy agreement with Apitope International NV.2. Past Member of SAB for Peptide therapeutics, TEVA and GSK BIO (vaccine safety advisory board). Advisor to Hoffman La Roche on autoimmune therapeutics. Advisor to Novartis on Influenza Vaccine Adjuvant Safety. 3. Non-profit. Advisor to DTI on Stem Cell Therapies 4. Non-profit. Advisor to Food Standards Agency on Peanut Allergy

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Apitope International NV and UCB Celltech.

    Research Support, Government Entities:

    1. MRC. MR/K007645/1. 2013-2016

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Wellcome Trust Programme grant #09107

    Stock/Stock Options/Board of Directors Compensation:

    1. 1. Apitope Intl. NV. Holds stock and stock options in Apitope Intl NV and receives travel costs for attending Apitope board meetings.

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Apitope Intl NV 2006-Current

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. 1. Geron, expert witness European Patent Court. 2007, 2011

  1. From Apitope Technology Bristol Ltd. (H.B.S., R.R., K.F.M., D.C.W.), Bristol UK; School of Cellular and Molecular Medicine (H.B.S., D.C.W.) and School of Clinical Sciences (N.J.S.), University of Bristol, UK; and Southmead Hospital (N.J.S.), Bristol, UK.
  1. Correspondence to Dr. Wraith: d.c.wraith{at}bris.ac.uk
View Full Text

Article usage

Article usage: March 2015 to May 2022

AbstractFullPdfSource
Mar 201532029950Highwire
Mar 201504229pmc
Apr 201536114337Highwire
Apr 201509856pmc
May 201513616449Highwire
May 201505421pmc
Jun 20152216058Highwire
Jun 201508227pmc
Jul 20158416312Highwire
Jul 201507119pmc
Aug 2015686414Highwire
Aug 201505316pmc
Sep 2015595710Highwire
Sep 201507623pmc
Oct 2015326015Highwire
Oct 201505715pmc
Nov 201545467Highwire
Nov 201506624pmc
Dec 201562516Highwire
Dec 201505324pmc
Jan 201653494Highwire
Jan 2016010428pmc
Feb 201652539Highwire
Feb 201606024pmc
Mar 2016584811Highwire
Mar 2016010150pmc
Apr 201647635Highwire
Apr 201605918pmc
May 201646552Highwire
May 201604422pmc
Jun 201651469Highwire
Jun 201604317pmc
Jul 201657203Highwire
Jul 201606211pmc
Aug 201648810Highwire
Aug 20160539pmc
Sep 20163654Highwire
Sep 201606312pmc
Oct 20164582Highwire
Oct 201607217pmc
Nov 2016311010Highwire
Nov 201605313pmc
Dec 201635117Highwire
Dec 20160365pmc
Jan 20172284Highwire
Jan 20170333pmc
Feb 201723114Highwire
Feb 201704112pmc
Mar 201739115Highwire
Mar 201705115pmc
Apr 201728133Highwire
Apr 2017163842pmc
May 201722116Highwire
May 2017153233pmc
Jun 20171234Highwire
Jun 2017121720pmc
Jul 20171382Highwire
Jul 201721921pmc
Aug 201723910Highwire
Aug 2017103144pmc
Sep 2017611Highwire
Sep 2017203937pmc
Oct 20172399Highwire
Oct 2017133137pmc
Nov 201720910Highwire
Nov 2017114348pmc
Dec 20170277Highwire
Jan 20185246Highwire
Feb 20186275Highwire
Mar 201811288Highwire
Apr 20181314Highwire
Apr 2018102934pmc
May 20182587Highwire
Jun 20181625Highwire
Jun 201852829pmc
Jul 20181366Highwire
Aug 20183593Highwire
Aug 2018102425pmc
Sep 201811283Highwire
Oct 20186384Highwire
Nov 20189458Highwire
Dec 20186431Highwire
Jan 20198256Highwire
Feb 201921267Highwire
Mar 201983198Highwire
Apr 201911398Highwire
May 201993348Highwire
Jun 201953247Highwire
Jul 2019127206Highwire
Aug 20192121613Highwire
Sep 2019206207Highwire
Oct 20192073413Highwire
Nov 2019144136Highwire
Dec 201987226Highwire
Jan 20202168Highwire
Feb 202032510Highwire
Mar 2020106216Highwire
Apr 20203147Highwire
May 202033614Highwire
Jun 20205179Highwire
Jul 20200255Highwire
Aug 20201188Highwire
Sep 202032013Highwire
Oct 202035116Highwire
Nov 202031814Highwire
Dec 202012410Highwire
Jan 202171415Highwire
Feb 202111718Highwire
Mar 202113918Highwire
Apr 20213214Highwire
May 20212173Highwire
Jun 20212286Highwire
Jul 20212227Highwire
Aug 202132714Highwire
Sep 202132013Highwire
Oct 202122826Highwire
Nov 202182726Highwire
Dec 202173515Highwire
Jan 202262514Highwire
Feb 20223179Highwire
Mar 20227216Highwire
Apr 20221699Highwire
May 202278815Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement